A bypass mechanism of abiraterone‐resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling
The Prostate2019Vol. 79(9), pp. 937–948
Citations Over TimeTop 13% of 2019 papers
J.M. Moll, Jinpei Kumagai, Martin E. van Royen, Wilma J. Teubel, Robert J. van Soest, Pim J. French, Yukio Homma, Guido Jenster, Ronald de Wit, Wytske M. van Weerden
Abstract
Activation of the AR by clinically relevant levels of Preg and Prog accumulating in abiraterone-treated patients may act as a driver for CRPC. These data provide a scientific rationale for combining CYP17A1 inhibitors with antiandrogens, particularly in patients with overexpressed or mutated-AR.
Related Papers
- → A drug safety evaluation of enzalutamide to treat advanced prostate cancer(2021)7 cited
- → Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer(2013)15 cited
- → Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer(2020)15 cited
- → Enzalutamide for the Treatment of Prostate Cancer: Results and Implications of the AFFIRM Trial(2014)12 cited
- → Limited Expression of Cytochrome P450 17α-Hydroxylase/17,20-Lyase in Prostate Cancer Cell Lines(2011)10 cited